Instituto Rosenbusch - Public Comps and Valuation Multiples

Instituto Rosenbusch Overview

About Instituto Rosenbusch

Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.

Founded

1948

HQ

Employees

n/a

Website

rosenbusch.com

Sectors

Biopharmaceuticals

Financials

Last FY Revenue $5.6M

Last FY EBITDA -$0.5M

EV

$5.4M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Instituto Rosenbusch Financials

See Instituto Rosenbusch valuation multiples based on analyst estimates

Instituto Rosenbusch P&L

In the most recent fiscal year, Instituto Rosenbusch reported revenue of $5.6M and EBITDA of -$0.5M.

Instituto Rosenbusch expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Instituto Rosenbusch valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$5.6M	XXX	XXX	XXX
Gross Profit	XXX	$2.6M	XXX	XXX	XXX
Gross Margin	XXX	46%	XXX	XXX	XXX
EBITDA	XXX	-$0.5M	XXX	XXX	XXX
EBITDA Margin	XXX	-9%	XXX	XXX	XXX
EBIT	XXX	$1.3M	XXX	XXX	XXX
EBIT Margin	XXX	24%	XXX	XXX	XXX
Net Profit	XXX	-$1.0M	XXX	XXX	XXX
Net Margin	XXX	-17%	XXX	XXX	XXX
Net Debt	XXX	$0.6M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Instituto Rosenbusch including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Instituto Rosenbusch achieved $5.6M in revenue and -$0.5M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$5.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$2.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	46.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	-$0.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	-9.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$1.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	23.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	-$1.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	-17.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$0.6M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Instituto Rosenbusch

This financial data table provides comprehensive performance metrics for Instituto Rosenbusch, a company based in Argentina. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Instituto Rosenbusch reported $5.6M in total revenue.
Fiscal year EBITDA was -$0.5M.
The company maintained a gross profit margin of 46.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was -9.4%.
Net profit margin reached -17.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Instituto Rosenbusch. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Instituto Rosenbusch Stock Performance

Instituto Rosenbusch has current market cap of ARS 6.7B (or $4.6M), and EV of ARS 8.0B (or $5.4M).

Market Cap Evolution

Instituto Rosenbusch Stock Data

As of September 23, 2025, Instituto Rosenbusch's stock price is ARS 158 (or $0).

See Instituto Rosenbusch trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$5.4M	$4.6M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Instituto Rosenbusch Valuation Multiples

Instituto Rosenbusch's trades at 1.5x EV/Revenue multiple, and 12.2x EV/EBITDA.

See valuation multiples for Instituto Rosenbusch and 15K+ public comps

Instituto Rosenbusch Financial Valuation Multiples

As of September 23, 2025, Instituto Rosenbusch has market cap of $4.6M and EV of $5.4M.

Equity research analysts estimate Instituto Rosenbusch's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Instituto Rosenbusch's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$4.6M	XXX	$4.6M	XXX	XXX	XXX
EV (current)	$5.4M	XXX	$5.4M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	1.5x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	12.2x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	14.5x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	99.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	38.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Instituto Rosenbusch Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Instituto Rosenbusch Margins & Growth Rates

Instituto Rosenbusch's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Instituto Rosenbusch's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Instituto Rosenbusch's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Instituto Rosenbusch and other 15K+ public comps

Instituto Rosenbusch Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	23%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial